Generic Name:
indacaterol /mometasone furoate
Project Status:
Complete
Therapeutic Area:
Asthma maintenance (adults, children 12 or older)
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Atectura Breezhaler
Project Line:
Reimbursement Review
Project Number:
SR0646-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
Indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. Atectura Breezhaler should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a LABA and an ICS.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. Atectura Breezhaler should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a LABA and an ICS.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.